Cognition Therapeutics Q2 Loss Narrows to $3.9M; Cash Runway Extended into Q4 2027
CGTX has more than doubled off its 52-week low of $0.55.
Summary
Cognition Therapeutics' Q2 loss narrowed to $3.9M, cash runway extends into Q4 2027, and the FDA aligned on a pivotal Phase 3 trial design for zervimesine in DLB psychosis.
Key Events · Earnings and Guidance · CGTX
-
Q2 Net Loss Narrows to $3.9M
Net loss improved to $3.9M from $6.7M in Q2 2025, driven by a 56% drop in R&D expenses as clinical trial activity winds down.
-
Cash Runway Extended into Q4 2027
Cash and equivalents of $34.0M at June 30, 2026, combined with remaining NIA grant funds, fund operations into Q4 2027 without additional ATM usage.
-
FDA Aligns on Pivotal Phase 3 for DLB Psychosis
The FDA concurred with the proposed Phase 3 trial design for zervimesine in DLB psychosis, a key step toward a registrational program.
-
ATM Usage in Q2 2026
The company sold 5.5M shares under its 2025 ATM for gross proceeds of ~$6.9M; $68.1M remains available.
Analysis · CGTX · Life Sciences
Cognition Therapeutics reported a significantly improved Q2 net loss of $3.9 million, down from $6.7 million a year ago, as R&D spending fell with the wind-down of late-stage trials. The company ended the quarter with $34.0 million in cash, enough to fund operations into the fourth quarter of 2027 without tapping its $68 million ATM. The filing also confirms FDA alignment on a pivotal Phase 3 trial for zervimesine in DLB psychosis, a key regulatory milestone. The combination of a shrinking loss, extended runway, and a clear registrational path reduces near-term survival risk for this $101 million market cap biotech.
At the time of this filing, CGTX was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.1M. The 52-week trading range was $0.55 to $3.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.